Synapse

← Lung Cancer Targets and Therapy

Papers in Lung Cancer Targets and Therapy

Page 1 · newest first

  1. Expert Consensus Recommendations on NSCLC Management: Evidence-Based Strategies for Early Resectable and Locally Advanced Disease from AsiaLung Cancer Targets and Therapy · 2026
  2. Identification of JAML as an Immune-Associated Prognostic Marker in Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2026
  3. Sunvozertinib in EGFR Exon 20 Insertion NSCLC: Approved but Not Available – Practical Dose Selection Considerations and Real-World Access ChallengesLung Cancer Targets and Therapy · 2026
  4. HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case ReportLung Cancer Targets and Therapy · 2026
  5. Exploratory Identification of Gene Copy Number Cut-Off for NGS-Based MET Amplification Assessment and Clinical Relevance to MET Inhibitor Outcomes in Non-Small-Cell Lung CancerLung Cancer Targets and Therapy · 2026
  6. Response to Selpercatinib in a CCDC6-RET Lung Adenocarcinoma with an Acquired Novel RET p.L730_G731insL After Progression on Pralsetinib: A Case ReportLung Cancer Targets and Therapy · 2026
  7. Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer PatientsLung Cancer Targets and Therapy · 2026
  8. Prospective Observational Real-World Study of Afatinib as First-Line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in ChinaLung Cancer Targets and Therapy · 2026
  9. Reduced Claudin-3 Expression Is Linked to Unfavorable Tumor Features and Poor Prognosis in Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2026
  10. Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case ReportLung Cancer Targets and Therapy · 2025
  11. Integrated Multi-Omics Approaches for Predicting Immune Checkpoint Inhibitor Response in NSCLC – Insights From Genomics, Proteomics, and MetabolomicsLung Cancer Targets and Therapy · 2025
  12. Tumor Heterogeneity and Plasticity in Small Cell Lung CancerLung Cancer Targets and Therapy · 2025
  13. A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025Lung Cancer Targets and Therapy · 2025
  14. Successful and On-going Long-Term Disease Control (>24 Months) with Gilteritinib in an ALK+ NSCLC Patient with Brain Metastasis Who Has Progressed on Multiple ALK TKIs. A Case Report and Review of Literature on GilteritnibLung Cancer Targets and Therapy · 2025
  15. Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study)Lung Cancer Targets and Therapy · 2025
  16. Epidermal Growth Factor Receptor Kinase Domain Duplication in Lung Adenocarcinoma with Sensitive Response to Afatinib: A Case Report and Literature ReviewLung Cancer Targets and Therapy · 2025
  17. Emerging Targets in Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2025
  18. Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma PatientsLung Cancer Targets and Therapy · 2025
  19. Elucidating the Role of FASN in Lung Cancer Stem Cells in Sensitive and Resistant EGFR-Mutated Non-Small Cell Lung Cancer CellsLung Cancer Targets and Therapy · 2025
  20. Genomic Profiling of Extensive Stage Small-Cell Lung Cancer Patients Identifies Molecular Factors Associated with SurvivalLung Cancer Targets and Therapy · 2025
  21. Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLCLung Cancer Targets and Therapy · 2025
  22. Adagrasib in KRYSTAL-12 has Not Broken the KRAS G12C Enigma Code of the Unspoken 6-Month PFS Barrier in NSCLCLung Cancer Targets and Therapy · 2024
  23. Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in KoreaLung Cancer Targets and Therapy · 2024
  24. NRG1 Fusions in NSCLC: Being eNRGy ConsciousLung Cancer Targets and Therapy · 2024
  25. Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2024
  26. Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H MutationLung Cancer Targets and Therapy · 2024
  27. Pulmonary Spindle Cell Carcinoma Mimicking Granulomatous Inflammation: A Rare Case Report and Brief Review of the LiteratureLung Cancer Targets and Therapy · 2024
  28. Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?Lung Cancer Targets and Therapy · 2024
  29. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.Lung Cancer Targets and Therapy · 2024
  30. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLCLung Cancer Targets and Therapy · 2024
  31. ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?Lung Cancer Targets and Therapy · 2024
  32. “ACHILLES” Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834)Lung Cancer Targets and Therapy · 2024
  33. HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2024
  34. MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?Lung Cancer Targets and Therapy · 2024
  35. Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory StudyLung Cancer Targets and Therapy · 2024
  36. Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must DeliverLung Cancer Targets and Therapy · 2024
  37. Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu’s ApproachLung Cancer Targets and Therapy · 2024
  38. Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?Lung Cancer Targets and Therapy · 2023
  39. Single-Cell Profiling of Tumor-Associated Neutrophils in Advanced Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2023
  40. Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to OsimertinibLung Cancer Targets and Therapy · 2023
  41. The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?Lung Cancer Targets and Therapy · 2023
  42. From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory SettingLung Cancer Targets and Therapy · 2023
  43. Effect of Lymphopenia on Tumor Response and Clinical Outcomes Following Chemoradiotherapy in Stage III Non-Small Cell Lung CancerLung Cancer Targets and Therapy · 2023
  44. CodeBreak 200: Sotorasib Has Not Broken the KRASG12C Enigma CodeLung Cancer Targets and Therapy · 2023
  45. CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLCLung Cancer Targets and Therapy · 2023
  46. Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive ReviewLung Cancer Targets and Therapy · 2023
  47. Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering InfernoLung Cancer Targets and Therapy · 2023
  48. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?Lung Cancer Targets and Therapy · 2022
  49. Arginine Deprivation in SCLC: Mechanisms and Perspectives for TherapyLung Cancer Targets and Therapy · 2022
  50. Deconstructing ADAURA. It is Not Yet Time to Forgo Platinum-based Adjuvant Chemotherapy in Resected Early Stage (IB-IIIA) EGFR-mutant NSCLCLung Cancer Targets and Therapy · 2022